Lung Cancer | Specialty

Effect of NGS Wait Time on Decision Making

March 30th 2020

Targeted Therapy Benefit for Actionable Mutations

March 30th 2020

The Impact of Upfront NGS Testing on Overall Outcomes

March 30th 2020

The Importance of NGS Testing in NSCLC

March 30th 2020

Multikinase TKI Toxicity Profile

March 30th 2020

The Role of Multikinase TKIs for NSCLC

March 30th 2020

MOA and Rationale for RET Inhibitor Development

March 30th 2020

The Importance of Targeting RET in NSCLC

March 30th 2020

Trastuzumab Deruxtecan Shows Promise Beyond Breast and Gastric Tumors

March 30th 2020

Fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody­–drug conjugate, demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types.

FDA Approves Durvalumab for Frontline Small Cell Lung Cancer

March 30th 2020

The FDA has approved durvalumab for the first-line treatment of adult patients with extensive-stage small cell lung cancer for use in combination with standard-of-care chemotherapy, which includes etoposide plus either carboplatin or cisplatin.

Tepotinib Approved in Japan for MET-Positive NSCLC

March 25th 2020

Tepotinib (Tepmetko) has been approved in Japan for the treatment of patients with non–small cell lung cancer harboring MET exon 14 skipping alterations.

Expert Perspectives in the Evolving ALK+ NSCLC Paradigm

March 24th 2020

In a wide-ranging discussion, Alexander Drilon, MD; Julia Rotow, MD; Thomas E. Stinchcombe, MD; and Ashish Saxena, MD, PhD, provide expert insight on developments in ALK-positive non–small cell lung cancer.

Plasma-Based TMB May Predict Pembrolizumab Response in NSCLC

March 24th 2020

Charu Aggarwal, MD, MPH, discusses the design and findings of an analysis examining the role of TMB as a predictive biomarker for pembrolizumab-based therapy in NSCLC.

Expert Shares Insight on Utility of Immunotherapy and Targeted Agents Across NSCLC

March 24th 2020

Gregory A. Otterson, MD, discusses the utility of immunotherapy in squamous non–small cell lung cancer and targeted the evolution of targeted therapy in biomarker-driven disease.

SCLC Paradigm Advances With Immunotherapy, Integration of Rapid Research Autopsies

March 23rd 2020

Hui-Zi Chen, MD, PhD, discusses the use of immunotherapy in ES-SCLC and the work being done to identify mechanisms of resistance to frontline therapy.

Updates in the ALK-Positive NSCLC Paradigm

March 23rd 2020

Advanced, recurrent, and metastatic NSCLC is often associated with poor prognosis, and treatment is aimed to extend survival and provide symptom management.

Research Aims to Augment OS Benefit With Osimertinib in EGFR+ NSCLC

March 23rd 2020

Erin M. Bertino, MD, discusses the current treatment landscape and next steps in the EGFR-mutant NSCLC paradigm.

Biomarker Hunt Garners Interest Amid New Standard of Care in NSCLC

March 21st 2020

Terence M. Williams, MD, PhD, discusses the impact of the PACIFIC trial on stage III NSCLC and how the hunt for prognostic biomarkers is underway across the lung cancer paradigm.

Biomarkers Inform Immunotherapy Decisions in Advanced NSCLC

March 20th 2020

Balazs Halmos, MD, MA, discusses the advances that have been made in the treatment of patients with metastatic non–small cell lung cancer, ongoing biomarker research, and the importance of molecular testing.

Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research

March 20th 2020

David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.